Incyte forward PE INCY

Share price divided by analysts' consensus earnings for the next twelve months, since 1996.

Today, Oct 23, 2026: 49.5×
9-year median: 31.7×
Against its 9-year history: 89th; percentile: 0 is its lowest day, 100 its highest
9-year range: 9.3× to 448×
Peer median: 24.4×

Incyte's forward PE is 49.5× as of Oct 23, 2026.

That is above its 9-year median of 31.7×, higher than on 89% of days in the last 9 years.

Over that time it ranged from 9.3× in May 2025 to 448× in Nov 2017.

The median for 10 biotech stocks of a similar size is 24.4×.

Forward PE over time

median 31.7×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	49.5×	39.7×	54.6×
2025	50.2×	9.3×	53.1×
2024	12.5×	12.3×	17.5×
2023	16.8×	13.9×	29.3×
2022	27.5×	26.4×	35.7×
2021	31.8×	25.5×	34.5×
2020	29.3×	27.4×	45.4×
2019	43.5×	33.6×	49.6×
2018	30.2×	28.5×	424×
2017	402×	402×	448×
2016	213×	196×	315×
2015	360×	333×	388×
2014	n/m a value too high to mean anything
2013	n/m a value too high to mean anything
2012	n/m a value too high to mean anything
2011	n/m a value too high to mean anything
2010	n/m a value too high to mean anything
2009	n/m a value too high to mean anything
2008	n/m a value too high to mean anything
2007	n/m a value too high to mean anything

Against its peers

Companies in Biotechnology nearest Incyte's size, closest first, today.

Company	Forward PE
INCYIncyte	49.5×
UTHRUnited Therapeutics	22.0×
ALNYAlnylam Pharmaceuticals	26.7×
EXELExelixis	n/m
NBIXNeurocrine Biosciences	n/m
HALOHalozyme Therapeutics	n/m
ONCBeOne Medicines	48.1×
TECHBIO-TECHNE	n/m
RGENRepligen	n/m
KRYSKrystal Biotech	n/m
REGNRegeneron Pharmaceuticals	12.6×
Peer median	24.4×

Where Incyte ranks

#51of 51Healthcare stocks with the lowest forward PE

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Incyte

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.